z-logo
open-access-imgOpen Access
Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1–17
Author(s) -
Jeremy S. Frieling,
Gemma Shay,
Victoria Izumi,
Sinéad Aherne,
Richard G. Saul,
Mikalai M. Budzevich,
John M. Koomen,
Conor C. Lynch
Publication year - 2017
Publication title -
oncogene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.395
H-Index - 342
eISSN - 1476-5594
pISSN - 0950-9232
DOI - 10.1038/onc.2017.70
Subject(s) - bone resorption , osteoclast , biology , matrix metalloproteinase , osteoblast , osteolysis , endocrinology , microbiology and biotechnology , medicine , parathyroid hormone , phosphorylation , regulator , bone remodeling , cancer research , in vitro , calcium , biochemistry , surgery , gene
Parathyroid hormone-related protein (PTHrP) is a critical regulator of bone resorption and augments osteolysis in skeletal malignancies. Here we report that the mature PTHrP 1-36 hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP 1-17 . PTHrP 1-17 retains the ability to signal through PTH1R to induce calcium flux and ERK phosphorylation but not cyclic AMP production or CREB phosphorylation. Notably, PTHrP 1-17 promotes osteoblast migration and mineralization in vitro, and systemic administration of PTHrP 1-17 augments ectopic bone formation in vivo. Further, in contrast to PTHrP 1-36 , PTHrP 1-17 does not affect osteoclast formation/function in vitro or in vivo. Finally, immunoprecipitation-mass spectrometry analyses using PTHrP 1-17 -specific antibodies establish that PTHrP 1-17 is indeed generated by cancer cells. Thus, matrix metalloproteinase-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote osteogenesis, indicating important roles for this circuit in bone remodelling in normal and disease contexts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here